Smad2 and 3 transcription factors control muscle mass in adulthood.

Loss of muscle mass occurs in a variety of diseases, including cancer, chronic heart failure, aquired immunodeficiency syndrome, diabetes, and renal failure, often aggravating pathological progression. Preventing muscle wasting by promoting muscle growth has been proposed as a possible therapeutic approach. Myostatin is an important negative modulator of muscle growth during myogenesis, and myostatin inhibitors are attractive drug targets. However, the role of the myostatin pathway in adulthood and the transcription factors involved in the signaling are unclear. Moreover, recent results confirm that other transforming growth factor-beta (TGF-beta) members control muscle mass. Using genetic tools, we perturbed this pathway in adult myofibers, in vivo, to characterize the downstream targets and their ability to control muscle mass. Smad2 and Smad3 are the transcription factors downstream of myostatin/TGF-beta and induce an atrophy program that is muscle RING-finger protein 1 (MuRF1) independent. Furthermore, Smad2/3 inhibition promotes muscle hypertrophy independent of satellite cells but partially dependent of mammalian target of rapamycin (mTOR) signaling. Thus myostatin and Akt pathways cross-talk at different levels. These findings point to myostatin inhibitors as good drugs to promote muscle growth during rehabilitation, especially when they are combined with IGF-1-Akt activators.

[1]  A. Pestronk,et al.  A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy , 2008, Annals of neurology.

[2]  Se-Jin Lee,et al.  Double muscling in cattle due to mutations in the myostatin gene. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Marco Sandri,et al.  Signaling in muscle atrophy and hypertrophy. , 2008, Physiology.

[4]  G. Yancopoulos,et al.  The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. , 2004, Molecular cell.

[5]  A. Goldberg,et al.  Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Wrana,et al.  Myostatin Signals through a Transforming Growth Factor β-Like Signaling Pathway To Block Adipogenesis , 2003, Molecular and Cellular Biology.

[7]  B. Langley,et al.  Myostatin Inhibits Myoblast Differentiation by Down-regulating MyoD Expression* , 2002, The Journal of Biological Chemistry.

[8]  Jiandie D. Lin,et al.  PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription , 2006, Proceedings of the National Academy of Sciences.

[9]  S. Anderson,et al.  Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation , 2004, Cell.

[10]  V. Sartorelli,et al.  Molecular and Cellular Determinants of Skeletal Muscle Atrophy and Hypertrophy , 2004, Science's STKE.

[11]  T. Zimmers,et al.  Induction of Cachexia in Mice by Systemically Administered Myostatin , 2002, Science.

[12]  W. Frontera,et al.  IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. , 2004, Cell.

[13]  A. Musarò,et al.  IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1 , 1999, Nature.

[14]  W. Mitch,et al.  Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. , 2004, Journal of the American Society of Nephrology : JASN.

[15]  D J Glass,et al.  Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy , 2001, Science.

[16]  Se-Jin Lee,et al.  Regulation of myostatin activity and muscle growth , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Nicholas Ling,et al.  Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF‐κB‐independent, FoxO1‐dependent mechanism , 2006 .

[18]  Denise M O'Hara,et al.  Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. , 2003, Biochemical and biophysical research communications.

[19]  S. Welle,et al.  Stimulation of skeletal muscle myofibrillar protein synthesis, p70 S6 kinase phosphorylation, and ribosomal protein S6 phosphorylation by inhibition of myostatin in mature mice. , 2009, American journal of physiology. Endocrinology and metabolism.

[20]  Se-Jin Lee,et al.  Quadrupling Muscle Mass in Mice by Targeting TGF-ß Signaling Pathways , 2007, PloS one.

[21]  Ugo Carraro,et al.  Functional in vivo gene transfer into the myofibers of adult skeletal muscle. , 2003, Biochemical and biophysical research communications.

[22]  G. Yancopoulos,et al.  Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo , 2001, Nature Cell Biology.

[23]  A. Goldberg,et al.  FoxO3 controls autophagy in skeletal muscle in vivo. , 2007, Cell metabolism.

[24]  W. N. Pappano,et al.  Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Marco Sandri,et al.  Foxo Transcription Factors Induce the Atrophy-Related Ubiquitin Ligase Atrogin-1 and Cause Skeletal Muscle Atrophy , 2004, Cell.

[26]  Antonio Musarò,et al.  Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle , 2001, Nature Genetics.

[27]  G. Yancopoulos,et al.  Conditional Activation of Akt in Adult Skeletal Muscle Induces Rapid Hypertrophy , 2004, Molecular and Cellular Biology.

[28]  D. Freyssenet,et al.  Ectopic expression of myostatin induces atrophy of adult skeletal muscle by decreasing muscle gene expression. , 2007, Endocrinology.

[29]  S. Hatakeyama,et al.  Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. , 2009, American journal of physiology. Cell physiology.

[30]  M. Matzuk,et al.  Regulation of muscle growth by multiple ligands signaling through activin type II receptors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  N. Offner,et al.  The initiation factor eIF3‐f is a major target for Atrogin1/MAFbx function in skeletal muscle atrophy , 2008, The EMBO journal.

[32]  E. Calabria,et al.  A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  N. Sonenberg,et al.  Atrophy of S6K1−/− skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control , 2005, Nature Cell Biology.

[34]  W. Frontera,et al.  IKKβ/NF-κB Activation Causes Severe Muscle Wasting in Mice , 2004, Cell.

[35]  Marc S. Williams.  Myostatin mutation associated with gross muscle hypertrophy in a child. , 2004, The New England journal of medicine.

[36]  J. Massagué,et al.  Smad transcription factors. , 2005, Genes & development.

[37]  D. Allen,et al.  Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors , 2007 .

[38]  A. Goldberg,et al.  Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  Se-Jin Lee,et al.  Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11 , 1999, Nature Genetics.

[40]  Wei He,et al.  A FoxO–Smad synexpression group in human keratinocytes , 2006, Proceedings of the National Academy of Sciences.

[41]  A. Goldberg,et al.  IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. , 2004, American journal of physiology. Endocrinology and metabolism.

[42]  A. Goldberg,et al.  Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  Florian Caiment,et al.  A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep , 2006, Nature Genetics.

[44]  Robert Walgate,et al.  Proliferation , 1985, Nature.

[45]  S. Welle,et al.  Muscle growth after postdevelopmental myostatin gene knockout. , 2007, American journal of physiology. Endocrinology and metabolism.

[46]  N. LeBrasseur,et al.  Fast/Glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. , 2008, Cell metabolism.

[47]  C. Bustamante,et al.  A Mutation in the Myostatin Gene Increases Muscle Mass and Enhances Racing Performance in Heterozygote Dogs , 2007, PLoS genetics.

[48]  T. Fielder,et al.  Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin. , 2003, American journal of physiology. Endocrinology and metabolism.

[49]  Se-Jin Lee.  Regulation of muscle mass by myostatin. , 2004, Annual review of cell and developmental biology.

[50]  Michiaki Yamashita,et al.  The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. , 2007, The Journal of clinical investigation.